On 6 January, the European Society of Neuroradiology (ESNR)/European Academy of Neurology (EAN) ARIA Work-ing Group published an article on readiness for amyloid-related imaging abnormalities (ARIA) monitoring in the Radiological Education journal. Amyloid-lowering immunotherapies aimed to slow the progres-sion of Alzheimer’s disease can cause brain bleeds and swell-ing, which require brain MRI for detection and monitoring. The Working Group ran a European survey to assess readiness for this logistical challenge and the need for further education. An online 32-item questionnaire was distributed to ESNR and EAN members. Between June and July 2024, 422 responses were collected from 41 European countries (47% neurologists, 51% (neuro)radiologists). Respondents included 15% residents and 58% worked in academic hospitals.
Sixty-nine percent reported familiarity with amyloid-related imaging abnormalities, and 60% reported understanding risk factors. Confidence in evaluating amyloid-related imaging abnormalities-edema/effusion and amyloid-related imaging abnormalities-haemorrhage was reported by 60% and 69%, with (neuro)radiologists more confident than neurologists. Thir-ty-four percent felt poorly equipped to meet logistical demands and 82% reported lacking a dedicated imaging protocol. Barri-ers included limited organisational adaptability and radiology expertise. Seventy-two percent saw potential in support from artificial intelligence approaches and 93% wanted further train-ing on monitoring. The article has been published open access and can be read here: https://doi.org/10.1007/s00330-025-12214-8